NASDAQ:ACRX - AcelRx Pharmaceuticals Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$2.51 +0.03 (+1.21 %)
(As of 01/18/2019 04:00 PM ET)
Previous Close$2.48
Today's Range$2.43 - $2.65
52-Week Range$1.65 - $5.05
Volume2.13 million shs
Average Volume1.65 million shs
Market Capitalization$145.48 million
P/E Ratio-2.28
Dividend YieldN/A
Beta2.02
AcelRx Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for the treatment of acute pain. Its lead product candidate is DSUVIA, a 30 mcg sufentanil sublingual tablet for the treatment of moderate-to-severe acute pain. The company also develops ZALVISO, a pre-programmed and patient-controlled analgesia system that allows hospital patients with moderate-to-severe acute pain to self-dose with sufentanil sublingual tablets to manage their pain. The company was formerly known as SuRx Pharmaceuticals, Inc. and changed its name to AcelRx Pharmaceuticals, Inc. in August 2006. AcelRx Pharmaceuticals, Inc. was founded in 2005 and is headquartered in Redwood City, California.

Receive ACRX News and Ratings via Email

Sign-up to receive the latest news and ratings for ACRX and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:ACRX
CUSIPN/A
Phone650-216-3500

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$7.99 million
Book Value($0.73) per share

Profitability

Net Income$-51,500,000.00
Net Margins-1,952.41%

Miscellaneous

Employees41
Market Cap$145.48 million
OptionableOptionable

AcelRx Pharmaceuticals (NASDAQ:ACRX) Frequently Asked Questions

What is AcelRx Pharmaceuticals' stock symbol?

AcelRx Pharmaceuticals trades on the NASDAQ under the ticker symbol "ACRX."

How were AcelRx Pharmaceuticals' earnings last quarter?

AcelRx Pharmaceuticals Inc (NASDAQ:ACRX) released its quarterly earnings data on Monday, November, 5th. The specialty pharmaceutical company reported ($0.21) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($0.20) by $0.01. The specialty pharmaceutical company had revenue of $0.38 million for the quarter, compared to analyst estimates of $1.10 million. View AcelRx Pharmaceuticals' Earnings History.

When is AcelRx Pharmaceuticals' next earnings date?

AcelRx Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Thursday, March 14th 2019. View Earnings Estimates for AcelRx Pharmaceuticals.

What price target have analysts set for ACRX?

7 Wall Street analysts have issued twelve-month target prices for AcelRx Pharmaceuticals' stock. Their predictions range from $7.00 to $10.00. On average, they anticipate AcelRx Pharmaceuticals' stock price to reach $8.6667 in the next twelve months. This suggests a possible upside of 245.3% from the stock's current price. View Analyst Price Targets for AcelRx Pharmaceuticals.

What is the consensus analysts' recommendation for AcelRx Pharmaceuticals?

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for AcelRx Pharmaceuticals in the last year. There are currently 1 hold rating and 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for AcelRx Pharmaceuticals.

What are Wall Street analysts saying about AcelRx Pharmaceuticals stock?

Here are some recent quotes from research analysts about AcelRx Pharmaceuticals stock:
  • 1. According to Zacks Investment Research, "AcelRx Pharmaceuticals, Inc., is a specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of pain. The Company product candidates comprises: ARX-01 or the Sufentanil NanoTab PCA System; ARX-02 or the Sufentanil NanoTab BTP Management System; and ARX-03 or the Sufentanil/Triazolam NanoTab which are in their development stage. Its product ARX-01 is focused on acute post-operative pain, ARX-02 is focused on the treatment of cancer breakthrough pain and ARX-03 is focused on providing mild sedation, anxiety reduction, and pain relief to patients undergoing painful procedures in a physician's office. AcelRx Pharmaceuticals, Inc. is headquartered in Redwood City, California. " (1/8/2019)
  • 2. Cantor Fitzgerald analysts commented, ". Post ACRX’s analyst day in NYC, we reiterate our Overweight rating and 12-month price target of $9. Despite Dsuvia approval on the large market opportunity ahead for the pain product, we believe the market continues to undervalue ACRX stock. The KOL’s in attendance today were very positive on their willingness to use Dsuvia in their respective emergency rooms and/or surgery centers, underscoring our positive thesis for Dsuvia’s prospects." (12/11/2018)
  • 3. HC Wainwright analysts commented, "916-3963, Probability of approval Risk-adj value Full value Dsuvia – U.S. 100% $8.06 $8.06 Shares outstanding 61,907 Zalviso – EU 100% $0.15 $0.15 Current share price $4.27 Discount rate 12.5% Zalviso – U.S." (11/6/2018)

Has AcelRx Pharmaceuticals been receiving favorable news coverage?

News headlines about ACRX stock have trended somewhat negative recently, according to InfoTrie Sentiment. The research group identifies positive and negative press coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. AcelRx Pharmaceuticals earned a news impact score of -1.0 on InfoTrie's scale. They also gave media coverage about the specialty pharmaceutical company a news buzz of 10.0 out of 10, meaning that recent press coverage is extremely likely to have an effect on the stock's share price in the next few days.

Who are some of AcelRx Pharmaceuticals' key competitors?

Who are AcelRx Pharmaceuticals' key executives?

AcelRx Pharmaceuticals' management team includes the folowing people:
  • Mr. Vincent J. Angotti, CEO & Director (Age 51)
  • Dr. Pamela Pierce Palmer, Co-Founder, Chief Medical Officer & Director (Age 56)
  • Mr. Raffi Mark Asadorian, Chief Financial Officer (Age 50)
  • Mr. Lawrence G. Hamel, Chief Devel. Officer (Age 67)
  • Mr. Anil N. Dasu, Chief Engineering Officer (Age 56)

How do I buy shares of AcelRx Pharmaceuticals?

Shares of ACRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is AcelRx Pharmaceuticals' stock price today?

One share of ACRX stock can currently be purchased for approximately $2.51.

How big of a company is AcelRx Pharmaceuticals?

AcelRx Pharmaceuticals has a market capitalization of $145.48 million and generates $7.99 million in revenue each year. The specialty pharmaceutical company earns $-51,500,000.00 in net income (profit) each year or ($1.10) on an earnings per share basis. AcelRx Pharmaceuticals employs 41 workers across the globe.

What is AcelRx Pharmaceuticals' official website?

The official website for AcelRx Pharmaceuticals is http://www.acelrx.com.

How can I contact AcelRx Pharmaceuticals?

AcelRx Pharmaceuticals' mailing address is 351 GALVESTON DRIVE, REDWOOD CITY CA, 94063. The specialty pharmaceutical company can be reached via phone at 650-216-3500 or via email at [email protected]


MarketBeat Community Rating for AcelRx Pharmaceuticals (NASDAQ ACRX)

Community Ranking:  2.8 out of 5 (star star)
Outperform Votes:  362 (Vote Outperform)
Underperform Votes:  296 (Vote Underperform)
Total Votes:  658
MarketBeat's community ratings are surveys of what our community members think about AcelRx Pharmaceuticals and other stocks. Vote "Outperform" if you believe ACRX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ACRX will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 1/18/2019 by MarketBeat.com Staff

Featured Article: Capital Gains

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel